Wave Life Sciences Ltd. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 46/100
What the filing says
Wave reported Q2 2026 net loss of $69.4M (vs. $50.5M prior year), revenue of $2.3M (vs. $8.7M), and R&D expenses of $51.3M (vs. $43.5M). Cash, equivalents, and marketable securities totaled $490.6M as of June 30, 2026, down from $602.1M at year-end 2025, with runway into 3Q 2028. Clinical progress: Phase 2a dosing underway in INLIGHT trial of WVE-007 (obesity); FDA meeting scheduled end of summer 2026 on WVE-006 (AATD) accelerated approval pathway; WVE-008 (PNPLA3 liver disease) CTA on track for 2H 2026.
Why this rating
Clinical pipeline advancement is positive, but worsening burn rate ($69.4M vs. $50.5M loss), declining revenue, and 18% cash depletion in 6 months offset gains. Cash runway to 3Q 2028 (~18 months) is adequate but creates near-term funding dependency. Moderate concern for clinical-stage biotech with multiple Phase 2 programs.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.